Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

This case report found that a patient with ritlecitinib-resistant alopecia areata experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential effectiveness and suggesting benefits of personalized treatment strategies targeting the JAK1-mediated pathway.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This study found that KRT6A expression increases after epidermal barrier disruption, worsening skin inflammation in disease conditions, and suggests that targeting KRT6A could offer a new treatment approach for inflammatory skin diseases linked to epidermal dysfunction.